1887

Abstract

Foot-and-mouth disease virus (FMDV) displays various epitopes on the capsid outer surface. In addition to the five neutralizing antigenic sites, there is evidence of the existence of other, yet unidentified, epitopes that are believed to play a role in antibody-mediated protection. Previous attempts to identify these epitopes revealed two additional substitutions at positions VP2-74 and -191 (5M2/5 virus) to be of antigenic significance. However, complete resistance to neutralization was not obtained in the neutralization assay, indicating the existence of other, undisclosed epitopes. Results from this study provides evidence of at least two new neutralizing epitopes involving residues VP3-116 and -195 around the threefold axis that have significant impact on the antigenic nature of the virus. These findings extend our knowledge of the surface features of the FMDV capsid known to elicit neutralizing antibodies, and should help with rational vaccine design.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001259
2019-04-16
2019-10-17
Loading full text...

Full text loading...

/deliver/fulltext/jgv/100/5/804.html?itemId=/content/journal/jgv/10.1099/jgv.0.001259&mimeType=html&fmt=ahah

References

  1. Mattion N, König G, Seki C, Smitsaart E, Maradei E et al. Reintroduction of foot-and-mouth disease in Argentina: characterisation of the isolates and development of tools for the control and eradication of the disease. Vaccine 2004;22:4149–4162 [CrossRef][PubMed]
    [Google Scholar]
  2. Paton DJ, Valarcher JF, Bergmann I, Matlho OG, Zakharov VM et al. Selection of foot and mouth disease vaccine strains-a review. Rev Sci Tech 2005;24:981–993
    [Google Scholar]
  3. Parida S. Vaccination against foot-and-mouth disease virus: strategies and effectiveness. Expert Rev Vaccines 2009;8:347–365 [CrossRef][PubMed]
    [Google Scholar]
  4. Mahapatra M, Parida S. Foot and mouth disease vaccine strain selection: current approaches and future perspectives. Expert Rev Vaccines 2018;17:577–591 [CrossRef][PubMed]
    [Google Scholar]
  5. Rweyemamu M, Roeder P, Mackay D, Sumption K, Brownlie J et al. Epidemiological patterns of foot-and-mouth disease worldwide. Transbound Emerg Dis 2008;55:57–72 [CrossRef][PubMed]
    [Google Scholar]
  6. Ayelet G, Mahapatra M, Gelaye E, Egziabher BG, Rufeal T et al. Genetic characterization of foot-and-mouth disease viruses, Ethiopia, 1981-2007. Emerg Infect Dis 2009;15:1409–1417 [CrossRef][PubMed]
    [Google Scholar]
  7. Pay TW, Hingley PJ. Correlation of 140S antigen dose with the serum neutralizing antibody response and the level of protection induced in cattle by foot-and-mouth disease vaccines. Vaccine 1987;5:60–64 [CrossRef][PubMed]
    [Google Scholar]
  8. Lea S, Hernández J, Blakemore W, Brocchi E, Curry S et al. The structure and antigenicity of a type C foot-and-mouth disease virus. Structure 1994;2:123–139 [CrossRef][PubMed]
    [Google Scholar]
  9. Borley DW, Mahapatra M, Paton DJ, Esnouf RM, Stuart DI et al. Evaluation and use of in-silico structure-based epitope prediction with foot-and-mouth disease virus. PLoS One 2013;8:e61122 [CrossRef][PubMed]
    [Google Scholar]
  10. Reeve R, Borley DW, Maree FF, Upadhyaya S, Lukhwareni A et al. Tracking the antigenic evolution of foot-and-mouth disease virus. PLoS One 2016;11:e0159360 [CrossRef][PubMed]
    [Google Scholar]
  11. Rojas ER, Carrillo E, Schiappacassi M, Campos R. Modification of foot-and-mouth disease virus O1 Caseros after serial passages in the presence of antiviral polyclonal sera. J Virol 1992;66:3368–3372[PubMed]
    [Google Scholar]
  12. Borrego B, Novella IS, Giralt E, Andreu D, Domingo E. Distinct repertoire of antigenic variants of foot-and-mouth disease virus in the presence or absence of immune selection. J Virol 1993;67:6071–6079[PubMed]
    [Google Scholar]
  13. Schiappacassi M, Rieder Rojas E, Carrillo E, Campos R. Response of foot-and-mouth disease virus C3 Resende to immunological pressure exerted in vitro by antiviral polyclonal sera. Virus Res 1995;36:77–85 [CrossRef][PubMed]
    [Google Scholar]
  14. Sarangi LN, Mohapatra JK, Subramaniam S, Sanyal A, Pattnaik B. Antigenic site variation in foot-and-mouth disease virus serotype O grown under vaccinal serum antibodies in vitro. Virus Res 2013;176:273–279 [CrossRef][PubMed]
    [Google Scholar]
  15. Mahapatra M, Aggarwal N, Cox S, Statham RJ, Knowles NJ et al. Evaluation of a monoclonal antibody-based approach for the selection of foot-and-mouth disease (FMD) vaccine strains. Vet Microbiol 2008;126:40–50 [CrossRef][PubMed]
    [Google Scholar]
  16. Xie QC, McCahon D, Crowther JR, Belsham GJ, McCullough KC. Neutralization of foot-and-mouth disease virus can be mediated through any of at least three separate antigenic sites. J Gen Virol 1987;68:1637–1647 [CrossRef][PubMed]
    [Google Scholar]
  17. McCahon D, Crowther JR, Belsham GJ, Kitson JD, Duchesne M et al. Evidence for at least four antigenic sites on type O foot-and-mouth disease virus involved in neutralization; identification by single and multiple site monoclonal antibody-resistant mutants. J Gen Virol 1989;70:639–645 [CrossRef][PubMed]
    [Google Scholar]
  18. Kitson JD, McCahon D, Belsham GJ. Sequence analysis of monoclonal antibody resistant mutants of type O foot and mouth disease virus: evidence for the involvement of the three surface exposed capsid proteins in four antigenic sites. Virology 1990;179:26–34 [CrossRef][PubMed]
    [Google Scholar]
  19. Crowther JR, Farias S, Carpenter WC, Samuel AR. Identification of a fifth neutralizable site on type O foot-and-mouth disease virus following characterization of single and quintuple monoclonal antibody escape mutants. J Gen Virol 1993;74:1547–1553 [CrossRef][PubMed]
    [Google Scholar]
  20. Barnett PV, Samuel AR, Pullen L, Ansell D, Butcher RN et al. Monoclonal antibodies, against O1 serotype foot-and-mouth disease virus, from a natural bovine host, recognize similar antigenic features to those defined by the mouse. J Gen Virol 1998;79:1687–1697 [CrossRef][PubMed]
    [Google Scholar]
  21. Aktas S, Samuel AR. Identification of antigenic epitopes on the foot and mouth disease virus isolate O1/Manisa/Turkey/69 using monoclonal antibodies. Rev Sci Tech 2000;19:744–753 [CrossRef][PubMed]
    [Google Scholar]
  22. Dunn CS, Samuel AR, Pullen LA, Anderson J. The biological relevance of virus neutralisation sites for virulence and vaccine protection in the guinea pig model of foot-and-mouth disease. Virology 1998;247:51–61 [CrossRef][PubMed]
    [Google Scholar]
  23. Asfor AS, Upadhyaya S, Knowles NJ, King DP, Paton DJ et al. Novel antibody binding determinants on the capsid surface of serotype O foot-and-mouth disease virus. J Gen Virol 2014;95:1104–1116 [CrossRef][PubMed]
    [Google Scholar]
  24. Mahapatra M, Upadhyaya S, Aviso S, Babu A, Hutchings G et al. Selection of vaccine strains for serotype O foot-and-mouth disease viruses (2007-2012) circulating in Southeast Asia, East Asia and Far East. Vaccine 2017;35:7147–7153 [CrossRef][PubMed]
    [Google Scholar]
  25. Lloyd-Jones K, Mahapatra M, Upadhyaya S, Paton DJ, Babu A et al. Genetic and antigenic characterization of serotype O FMD viruses from East Africa for the selection of suitable vaccine strain. Vaccine 2017;35:6842–6849 [CrossRef][PubMed]
    [Google Scholar]
  26. Grazioli S, Fallacara F, Brocchi E. Mapping of antigenic sites of foot-and-mouth disease virus serotype Asia 1 and relationships with sites described in other serotypes. J Gen Virol 2013;94:559–569 [CrossRef][PubMed]
    [Google Scholar]
  27. Thomas AA, Woortmeijer RJ, Puijk W, Barteling SJ. Antigenic sites on foot-and-mouth disease virus type A10. J Virol 1988;62:2782–2789[PubMed]
    [Google Scholar]
  28. Mahapatra M, Hamblin P, Paton DJ. Foot-and-mouth disease virus epitope dominance in the antibody response of vaccinated animals. J Gen Virol 2012;93:488–493 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.001259
Loading
/content/journal/jgv/10.1099/jgv.0.001259
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error